Healthcare and Pharmaceuticals industry

Global Recombinant Therapeutic Antibodies and Proteins Market Size Share Forecast 2025




 

Impact Analysis of Covid-19

The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Recombinant therapeutic protein drugs are an important class of medicines, which helps patients in need of novel therapies. Recently approved recombinant protein therapeutics have been developed to treat a wide variety of clinical indications, including cancers, inflammation/autoimmunity, genetic disorders, and exposure to infectious agents. The latest advancements in protein-engineering technologies have allowed drug manufacturers and developers to adjust desirable functional characteristics of proteins of interest maintaining product efficacy. Protein-based therapies are highly successful and experience unparalleled growth potential in terms of their efficacy.
Market Dynamics
Recombinant therapeutic proteins and antibodies have gained high traction in clinical applications. Due to development of antibody-based therapeutics, mammalian expression systems have experienced a major boost and microbial expression systems continue to be widely used in industries, which in turn will fuel growth of the market. However, variations in production methods of therapeutic antibodies can lead to differences in their structure, based on the selection of recombinant procedure. Most protein therapeutics available in the market are recombinant and majority of them are in clinical trials for therapy of immune disorders, cancers, infections, and other diseases. Various engineered proteins, including multi-specific fusion proteins, bi-specific monoclonal antibodies (mAbs) and mAbs conjugated small molecule drugs, and proteins with optimized pharmacokinetics are under development.
Key features of the study:

This report provides in-depth analysis of recombinant therapeutic antibodies and proteins market and provides market size (US$ Million) and cumulative annual growth rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global recombinant therapeutic antibodies and proteins market based on the following parameters – company overview, financial performance, product portfolio, market presence, key developments, strategies, and future plans
Key companies covered as a part of this study include Abbott, Amgen Inc., Biogen Inc., Eli Lilly and Company, F. Hoffmann-La Roche, Johnson and Johnson, Merck & Co., Novo Nordisk, Pfizer Inc., and Sanofi S.A.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global recombinant therapeutic antibodies and proteins market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the recombinant therapeutic antibodies and proteins market

Detailed Segmentation:

Global Recombinant Therapeutic Antibodies and Proteins Market, By Drug Class:

Plasma Protein
Growth Factors
Fusion Proteins
Monoclonal Antibodies
Hormones
Enzyme
Coagulation Factors
Others

Global Recombinant Therapeutic Antibodies and Proteins Market, By Application:

Oncology
Hematology
Immunology
Endocrinology
Infectious Disease
Cardiovascular Diseases
Others

Global Recombinant Therapeutic Antibodies and Proteins Market, By Geography:

North America Recombinant Therapeutic Antibodies and Proteins Market

By Drug Class:

Plasma Protein
Growth Factors
Fusion Proteins
Monoclonal Antibodies
Hormones
Enzyme
Coagulation Factors
Others

By Application:

Oncology
Hematology
Immunology
Endocrinology
Infectious Disease
Cardiovascular Diseases
Others

By Country:

U.S.
Canada


Latin America Recombinant Therapeutic Antibodies and Proteins Market

By Drug Class:

Plasma Protein
Growth Factors
Fusion Proteins
Monoclonal Antibodies
Hormones
Enzyme
Coagulation Factors
Others

By Application:

Oncology
Hematology
Immunology
Endocrinology
Infectious Disease
Cardiovascular Diseases
Others

By Country:

Brazil
Mexico
Argentina
Rest of Latin America


Europe Recombinant Therapeutic Antibodies and Proteins Market

By Drug Class:

Plasma Protein
Growth Factors
Fusion Proteins
Monoclonal Antibodies
Hormones
Enzyme
Coagulation Factors
Others

By Application:

Oncology
Hematology
Immunology
Endocrinology
Infectious Disease
Cardiovascular Diseases
Others

By Country:

Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe


Asia Pacific Recombinant Therapeutic Antibodies and Proteins Market

By Drug Class:

Plasma Protein
Growth Factors
Fusion Proteins
Monoclonal Antibodies
Hormones
Enzyme
Coagulation Factors
Others

By Application:

Oncology
Hematology
Immunology
Endocrinology
Infectious Disease
Cardiovascular Diseases
Others

By Country:

China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific


Middle East Recombinant Therapeutic Antibodies and Proteins Market

By Drug Class:

Plasma Protein
Growth Factors
Fusion Proteins
Monoclonal Antibodies
Hormones
Enzyme
Coagulation Factors
Others

By Application:

Oncology
Hematology
Immunology
Endocrinology
Infectious Disease
Cardiovascular Diseases
Others

By Country:

GCC
Israel
Rest of Middle East


Africa Recombinant Therapeutic Antibodies and Proteins Market

By Drug Class:

Plasma Protein
Growth Factors
Fusion Proteins
Monoclonal Antibodies
Hormones
Enzyme
Coagulation Factors
Others

By Application:

Oncology
Hematology
Immunology
Endocrinology
Infectious Disease
Cardiovascular Diseases
Others

By Country:

North Africa
South Africa
Central Africa



Company Profiles

Abbott Laboratories*

Company Overview
Product Portfolio
Key Highlights
Financial Overview
Market Strategy

Amgen Inc.
Biogen Inc.
Eli Lilly and Company
F. Hoffmann-La Roche
Johnson and Johnson
Merck & Co.
Novo Nordisk
Pfizer, Inc.
Sanofi S.A.


“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objective and Assumption
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
o Market Definition and Scope
o Executive Summary
o Market Snippet, By Drug Class
o Market Snippet, By Application
o Market Snippet, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
o Drivers
o Restraints
o Market Opportunities
o Market Trends
o Pipeline Analysis
o Drug Development Challenges
o New Market Entrants
o Regulatory Scenario
o PEST Analysis
o Porter's Analysis
4. Global Recombinant Therapeutic Antibodies and Proteins Market, By Drug Class, 2016 - 2026, (US$ Million)
o Introduction
o Market Share Analysis, 2018 and 2026 (%)
o Y-o-Y Growth Analysis, 2017-2026
o Segment Trends
o Plasma Protein
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
o Growth Factors
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
o Fusion Proteins
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
o Monoclonal Antibodies
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
o Hormones
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
o Enzyme
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
o Coagulation Factors
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
o Others
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
5. Global Recombinant Therapeutic Antibodies and Proteins Market, Application, 2016 - 2026, (US$ Million)
o Introduction
o Market Share Analysis, 2018 and 2026 (%)
o Y-o-Y Growth Analysis, 2017-2026
o Segment Trends
o Oncology
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
o Hematology
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
o Immunology
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
o Endocrinology
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
o Infectious Disease
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
o Cardiovascular Disease
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
o Others
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
6. Global Recombinant Therapeutic Antibodies and Proteins Market, By Region, 2016 - 2026, (US$ Million)
o Introduction
o Market Share Analysis, By Region, 2018 and 2026 (%)
o Y-o-Y Growth Analysis, For Regions, 2017-2026
o Regional Trends
o North America
o Market Size and Forecast, By Drug Class, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
o U.S.
o Canada
o Latin America
o Market Size and Forecast, By Drug Class, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
o Market Size and Forecast, By Drug Class, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
o Germany
o U.K.
o France
o Italy
o Spain
o Russia
o Rest of Europe
o Asia Pacific
o Market Size and Forecast, By Drug Class, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
o China
o India
o Japan
o Australia
o South Korea
o ASEAN
o Rest of Asia Pacific
o Middle East
o Market Size and Forecast, By Drug Class, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
o GCC
o Israel
o Rest of Middle East
o Africa
o Market Size and Forecast, By Drug Class, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
o South Africa
o Central Africa
o North Africa
7. Competitive Landscape
o Heat Map Analysis
o Company Profiles
o Abbott*
o Company Overview
o Product Portfolio
o Key Highlights
o Financial Overview
o Market Strategy
o Amgen Inc.
o Company Overview
o Product Portfolio
o Key Highlights
o Financial Overview
o Market Strategy
o Biogen Inc.
o Company Overview
o Product Portfolio
o Key Highlights
o Financial Overview
o Market Strategy
o Eli Lilly and Company
o Company Overview
o Product Portfolio
o Key Highlights
o Financial Overview
o Market Strategy
o F. Hoffmann-La Roche
o Company Overview
o Product Portfolio
o Key Highlights
o Financial Overview
o Market Strategy
o Johnson and Johnson
o Company Overview
o Product Portfolio
o Key Highlights
o Financial Overview
o Market Strategy
o Merck & Co.
o Company Overview
o Product Portfolio
o Key Highlights
o Financial Overview
o Market Strategy
o Novo Nordisk
o Company Overview
o Product Portfolio
o Key Highlights
o Financial Overview
o Market Strategy
o Pfizer Inc.
o Company Overview
o Product Portfolio
o Key Highlights
o Financial Overview
o Market Strategy
o Sanofi S.A.
o Company Overview
o Product Portfolio
o Key Highlights
o Financial Overview
o Market Strategy
o Analyst Views
8. Section
o References
o Research Methodology
o About us and Sales Contact
*Browse 22 market data tables and 27 figures on "Recombinant Therapeutic Antibodies and Proteins Market - Global forecast to 2026".

 



Frequently Asked Questions

The report efficiently evaluates the market from various dimensions to deliver an end-product that is informative, elaborate, and accurate and includes detailed market segmentation, regional analysis, and competitive landscape of the industry.
The report efficiently evaluates the current market size and provides industry forecast. The market was valued at xx Million US$ in 2019, and is expected to grow at a CAGR of xx% during the period 2020-2027.
The report efficiently evaluates the current market size and provides forecast for the industry in terms of Value (US$ Mn) and Volume (Mn Units).
Market is segmented by Product Types, Drug Class, Indication, Applications, Services Types, End-users, Distribution channel, and Regions.
The report presents the current market size, and market forecast, market opportunities, key drivers and restraints, pipeline Analysis, incidence rate, epidemiology analysis, prevalence rate, regulatory scenario, industry trend, PESTLE analysis, PORTER’s analysis, new product approvals/launch, promotion and marketing initiatives, pricing analysis, export-import analysis, trade analysis, competitive landscape which help businesses in decision making. The analysis data is based on current and historical market trends which help in investment related decisions.
Custom research is crucial components of the business strategy which helps any organization to gain insight into specific business sector, aligned with specific area of interest. Thus, SMI offers more accurate, pragmatic, and actionable information specifically tailored to suit your business needs.

Get In Touch

In search of customized market research solution? We are here to help you. Contact us.